Market Research Logo

Cardiac Biomarkers: Technologies and Global Markets

Cardiac Biomarkers: Technologies and Global Markets

The global cardiac biomarkers market has grown to $4.9 billion in 2015 from $4.4 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.

This report provides:
An overview of the global market for cardiac biomarkers and related technologies.
Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
Clinical guidelines and government regulations.
Profiles of major players in the industry.


SCOPE OF REPORT

Current and projected assay revenues during the forecast period (2015 through 2020) are presented. In addition, newly developed assays with regulatory approval and others expected to receive U.S. Food and Drug Administration approval within the forecast period are also projected. Figures for 2015 are estimated, except where actual results have been reported, because of the timing of the release of this report. For large market segments, such as cTn and natriuretic peptides, the analytical sensitivities and cutoff references for the diagnosis and prognosis values are discussed in detail. Moreover, the ongoing effort in developing a high-sensitivity troponin assay, as well as the attempt to pursue additional biomarkers for the diagnosis of congestive heart failure (CHF) and strokes are focused on in this study.

The report includes an analysis of leading and emerging competitors in the current global diagnostics market for CVDs. Profiles of manufacturers of leading products as well as biotechnology companies with products in development are discussed to define their specific product strategies. The competitive environment is examined, with a special focus on how instrumentation type (clinical chemistry analyzers compared with point-of-care devices) and their respective technologies are influencing the current standard of care. Detailed profiles of current market leaders are discussed, as well as companies with innovative products poised to enter the market during the forecast period.

Market figures are based on revenues at the manufacturers’ level and are projected at 2015-U.S.-dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, new product introductions, expanded indications for existing products and projected changes in the prevalence and diagnosis of respective diseases. Included in this report are forecasts by product, product category and by company from 2014 through 2020. The study is arranged to offer an overview of the diagnostics market accompanied by product, company and region.

Excluded from this report are nonproteomic diagnoses (i.e., molecular diagnostics), imaging technology and pharmaceutical biomarkers. Sales figures are reported in U.S. dollars, and in each case, these reflect currency fluctuations within the performance of changes in sales. Sales figures do not account for variation in local currencies. All market share data presented are on a global basis, unless specifically noted.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL CARDIAC BIOMARKER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL CARDIAC BIOMARKER MARKET BY REGION, 2014-2020 ($ MILLIONS)
CHAPTER 3 OVERVIEW
MAJOR TRENDS IN THE CARDIAC BIOMARKERS MARKET
DEVELOPMENT OF POINT-OF-CARE BIOMARKERS MARKET
IMPROVED CLINICAL AND ANALYTICAL SENSITIVITY
CHINA TO BE THE LEADING FORCE IN THE ASIAN MARKET
FIGURE 1 NUMBER OF PATENTS BY COUNTRY, IT* AND HEALTHCARE, 2013 (NO. OF PATENTS)
GLOBAL INCREASE IN LIFESTYLE-ORIENTED DISEASES AND FATALITIES
PATENT TRENDS
Cardiac Biomarkers Patent by Region
FIGURE 2 NUMBER OF CARDIAC BIOMARKER PATENTS BY REGION*, 2011-2015 (NO. OF PATENTS)
Cardiac Biomarkers by Stakeholders
FIGURE 3 SHARES OF STAKEHOLDERS IN CARDIAC BIOMARKERS PATENTS, 2011-2015 (NO./%)
Patents by Assignee
FIGURE 4 NUMBER OF CARDIAC BIOMARKER PATENTS BY ASSIGNEE, 2011-2015 (NO. OF PATENTS)
STRATEGIC TRENDS
FIGURE 5 TOP STRATEGIES, 2011-2015 (NUMBER)
TYPE OF BIOMARKERS
PREDICTIVE
DIAGNOSTIC
GOLD STANDARD OF CARDIAC BIOMARKERS
BIOMARKER DISCOVERY AND VALIDATION
BIOMARKER CANDIDATE SCREENING
BIOMARKER CANDIDATE VALIDATION
ALTERNATIVE MARKETS
DIAGNOSTIC DEVICES
CORONARY ANGIOGRAPHY
TABLE 1 PRICE RANGE OF CORONARY ANGIOGRAPHY/CT ANGIOGRAPHY ($)
MAGNETIC RESONANCE ANGIOGRAM
X-RAY IMAGING
ECHOCARDIOGRAPHY
TABLE 2 DIFFERENT BRANDS AND COST OF ECG MACHINES ($)
RELATED MARKETS
PROTEOMICS
END USERS AND STAKEHOLDERS IN THE BIOMARKER INDUSTRY
HOSPITALS AND ACADEMIA
TABLE 3 LEADING HOSPITALS AND INSTITUTES INVOLVED IN BIOMARKER
STUDY
CONTRACT RESEARCH ORGANIZATIONS
BIOTECHNOLOGY COMPANIES
TABLE 4 COMPANIES INVOLVED IN BIOMARKER STUDIES
EPIDEMIC OF CARDIOVASCULAR DISEASE
TABLE 5 EPIDEMIC OF CARDIOVASCULAR DISEASES, 2015
RISK FACTORS AND PREVENTION OF CARDIOVASCULAR DISEASE
FIGURE 6 GLOBAL DISTRIBUTION OF CARDIOVASCULAR DISEASE: DALY, 2004 (PER 100,000 PEOPLE)
FIGURE 7 GLOBAL CARDIOVASCULAR DISEASE TRENDS, 2011-2018 (MILLION CASES)
CLASSIFICATION OF CARDIOVASCULAR DISEASE
CORONARY HEART DISEASE
TABLE 6 DISEASE PROFILE: CORONARY HEART DISEASE
TABLE 7 HEART DISEASE PERCENTAGE IN DIFFERENT RACES AND ETHNICITIES, 2013 (%)
ACUTE MYOCARDIAL INFARCTION
TABLE 8 DISEASE PROFILE: ACUTE MYOCARDIAL INFARCTION
HYPERTENSIVE HEART DISEASE
TABLE 9 DISEASE PROFILE OF HYPERTENSIVE HEART DISEASE
CEREBROVASCULAR DISEASE
TABLE 10 DISEASE PROFILE: CEREBROVASCULAR DISEASE
CONGESTIVE HEART FAILURE
TABLE 11 DISEASE PROFILE: CONGESTIVE HEART FAILURE
PERIPHERAL ARTERIAL DISEASE
OTHER DISEASES
TABLE 12 DISEASE PROFILE: HEMORRHAGIC STROKE
HISTORY AND CURRENT STATE OF HEART DISEASE
FUTURE DIRECTION OF CARDIAC BIOMARKERS DIAGNOSIS
BACKGROUND AND CLINICAL VALUE OF CARDIAC BIOMARKERS
BNP AND NT-PROBNP
C-REACTIVE PROTEIN
COPEPTIN
CREATINE KINASE MB
D-DIMER
GALECTIN-3
HEART FATTY ACID BINDING PROTEIN
MYOGLOBIN
TABLE 13 PRODUCT PROFILE: MYOGLOBIN
ST2
TABLE 14 BIOMARKER PROFILE: ST2
CARDIAC TROPONIN I/TROPONIN T
TABLE 15 PRODUCT PROFILE: TROPONIN
Description of Troponin Biomarkers
Troponin as the Preferred Biomarker
FIGURE 8 INTERPRETING ELEVATED LEVELS OF CARDIAC TROPONIN
CARDIAC BIOMARKERS UNDER DEVELOPMENT
Choline
Glial Fibrillary Acidic Protein
Ischemia-Modified Albumin
Myeloperoxidase
S100-Beta
CLINICAL GUIDELINES OF BIOMARKERS
TROPONIN/CK-MB/MYOGLOBLIN
BNP/NT-PROBNP
COPEPTIN
GALECTIN-3
C-REACTIVE PROTEIN
ST2
CHAPTER 4 INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS
INDUSTRY STRUCTURE
DIAGNOSTIC METHODS
IMMUNOASSAY
Radioimmunoassay
Enzyme-Linked Immunosorbent Assay
Chemiluminescent Enzyme Immunoassay
LIGHT SCATTERING
Turbidimetry
Nephelometry
Particle Counting
New Developments
LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
PATENT ANALYSIS
NEWLY ISSUED PATENTS
TABLE 16 PATENT TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2009-2015 (NO. OF PATENTS)
Patents on Assays
TABLE 17 PATENTS BY BIOMARKER CATEGORY, 2009-2015 (NO./%)
Patents by Manufacturer/Research Institute
TABLE 18 PATENTS BY COMPANY, 2009-2015 (NO./%)
TABLE 19 PATENTS ON CARDIAC BIOMARKER BY ASSIGNEE TYPE (NO./%)
TABLE 20 PATENT ANALYSIS BY REGION, 2009-2015 (NO./%)
TABLE 21 U.S. PATENT ANALYSIS, 2009-2015 (NO./%)
TABLE 22 EUROPEAN PATENT ANALYSIS, 2009-2015 (NO./%)
TABLE 23 PATENTS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, 2015
NEW PATENT APPLICATIONS
Patents by Focus
TABLE 24 PATENT APPLICATION TRENDS ON CARDIAC BIOMARKER ASSAYS USED FOR DIAGNOSTIC TESTING, APRIL-JUNE 2015 (NO.)
TABLE 25 EXAMPLES OF PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015
Patents by Manufacturer/Research Institute
TABLE 26 PATENT APPLICATIONS BY COMPANY, APRIL-JUNE 2015 (NO./%)
COMPETITIVE LANDSCAPE
FIGURE 9 RECENT KEY STRATEGIES OF CARDIAC BIOMARKER MARKET, 2011-2015 (NO./%)
TABLE 27 PARTNERSHIP AND COLLABORATION, 2011-2015
FIGURE 10 PARTNERSHIP AND COLLABORATION BY COMPANY,* 2011-2015 (NO./%)
PRODUCT APPROVALS AND PRODUCT CLEARANCES
TABLE 28 PRODUCT APPROVALS AND PRODUCT CLEARANCES, 2011-2015
FIGURE 11 PRODUCT APPROVALS AND PRODUCT CLEARANCES BY COMPANIES, 2011-2015 (NO./%)
NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES
TABLE 29 NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES, 2011-2015
FIGURE 12 NEW PRODUCT DEVELOPMENTS AND PRODUCT LAUNCHES BY COMPANY, 2011-2015 (NO./%)
MERGERS AND ACQUISITIONS
TABLE 30 MERGERS AND ACQUISITIONS, 2011-2015
FIGURE 13 MERGERS AND ACQUISITIONS BY COMPANY, 2011-2015 (NO./%)
OTHER STRATEGIES
TABLE 31 OTHER STRATEGIES, 2011-2015
GOVERNMENT REGULATION
U.S. FDA 501K APPROVAL
Division Acceptance and Review
Examples of U.S. FDA 501(k) Approval
CE MARKING IN EUROPE
Examples of CE Marking in Europe
OTHER INTERNATIONAL REGULATORY AGENCIES
TRENDS IN PRICE AND PRICE/PERFORMANCE
GENERAL TECHNOLOGY ISSUES
SENSITIVITY AND SPECIFICITY
POSITIVE AND NEGATIVE PREDICTIVE VALUES
RECEIVER OPERATOR CHARACTERISTIC CURVES
FIGURE 14 RECEIVER OPERATOR CHARACTERISTIC CURVES
CHAPTER 5 SUMMARY OF MARKET BY ASSAYS
TABLE 32 GLOBAL CARDIAC BIOMARKERS MARKET BY ASSAY CATEGORY, THROUGH 2020 ($ MILLIONS)
CHAPTER 6 MARKET BY INSTRUMENT
CLINICAL CHEMISTRY ANALYZERS
FUTURE OF CLINICAL CHEMISTRY ANALYZERS
POINT-OF-CARE DEVICES
FUTURE OF POINT-OF-CARE TESTING
MARKET BY INSTRUMENT CATEGORY
TABLE 33 GLOBAL CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 34 GLOBAL CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 35 GLOBAL BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 36 GLOBAL CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 37 GLOBAL NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 38 GLOBAL OTHER BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
CHAPTER 7 MARKET BY REGION
SUMMARY OF MARKET BY REGION
NORTH AMERICA
UNITED STATES
CANADA
TABLE 39 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
TABLE 40 NORTH AMERICA CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 41 NORTH AMERICA CTNI BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 42 NORTH AMERICA BNP AND NT-PROBNP BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 43 NORTH AMERICA CK-MB BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 44 NORTH AMERICA NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 45 NORTH AMERICA OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
EUROPEAN MARKET
UNITED KINGDOM
FRANCE
GERMANY
TABLE 46 EUROPEAN CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
TABLE 47 EUROPEAN CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 48 EUROPEAN CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 49 EUROPEAN BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 50 EUROPEAN CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 51 EUROPEAN NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 52 EUROPEAN OTHER BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
ASIA-PACIFIC MARKET
INDIA
CHINA
Regulations in China
JAPAN
Regulations in Japan
TABLE 53 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
TABLE 54 ASIA-PACIFIC CARDIAC BIOMARKER MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 55 ASIA-PACIFIC CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 56 ASIA-PACIFIC BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 57 ASIA-PACIFIC CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 58 ASI-PACIFIC NEW CHF BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 59 ASIA-PACIFIC MARKET FOR OTHER BIOMARKERS BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
MARKET IN THE REST OF THE WORLD
TABLE 60 REST OF WORLD CARDIAC BIOMARKERS MARKET BY ASSAY, THROUGH 2020 ($ MILLIONS)
TABLE 61 REST OF WORLD CARDIAC BIOMARKERS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 62 REST OF WORLD CTNI ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 63 REST OF WORLD BNP AND NT-PROBNP ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 64 REST OF WORLD CK-MB ASSAYS MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
TABLE 65 REST OF WORLD NEW BIOMARKERS* MARKET BY INSTRUMENT CATEGORY, THROUGH 2020 ($ MILLIONS)
CHAPTER 8 COMPANY PROFILES
ABBOTT DIAGNOSTICS
TABLE 66 ABBOTT DIAGNOSTICS: KEY PRODUCTS
TABLE 67 ABBOTT DIAGNOSTICS: RECENT DEVELOPMENTS
ALERE INC.
TABLE 68 ALERE INC.: KEY PRODUCTS
COMPANY STRATEGY
TABLE 69 ALERE INC.: RECENT DEVELOPMENTS
BECKMAN COULTER
TABLE 70 BECKMAN COULTER: KEY PRODUCTS
COMPANY STRATEGY
TABLE 71 BECKMAN COULTER: RECENT DEVELOPMENTS
BECTON, DICKINSON AND CO.
TABLE 72 BECTON, DICKINSON AND CO.: KEY PRODUCTS
COMPANY STRATEGY
TABLE 73 BECTON, DICKINSON AND CO.: RECENT DEVELOPMENTS
BG MEDICINE INC.
TABLE 74 BG MEDICINE INC: KEY PRODUCTS
TABLE 75 BG MEDICINE INC: RECENT DEVELOPMENTS
BIOMERIEUX
TABLE 76 BIOMERIEUX: KEY PRODUCTS
COMPANY STRATEGY
TABLE 77 BIOMERIEUX: RECENT DEVELOPMENTS
BIO-RAD LABORATORIES
TABLE 78 BIO-RAD LABORATORIES: KEY PRODUCTS
TABLE 79 BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
CISBIO BIOASSAYS
TABLE 80 CISBIO BIOASSAYS: KEY PRODUCTS
COVANCE
TABLE 81 COVANCE: KEY PRODUCTS
EKF DIAGNOSTICS
TABLE 82 EKF DIAGNOSTICS: KEY PRODUCTS
TABLE 83 EKF DIAGNOSTICS: RECENT DEVELOPMENTS
ENZO BIOCHEM INC.
TABLE 84 ENZO BIOCHEM INC.: KEY PRODUCTS
HOLOGIC INC.
TABLE 85 HOLOGIC INC.: KEY PRODUCTS
MESO SCALE DIAGNOSTICS
TABLE 86 MESO SCALE DIAGNOSTICS: KEY PRODUCTS
ORTHO CLINICAL DIAGNOSTICS
TABLE 87 ORTHO CLINICAL DIAGNOSTICS: KEY PRODUCTS
TABLE 88 ORTHO CLINICAL DIAGNOSTICS: RECENT DEVELOPMENTS
PACIFIC BIOMARKERS INC.
TABLE 89 PACIFIC BIOMARKERS INC.: KEY PRODUCTS (CARDIOVASCULAR)
TABLE 90 PACIFIC BIOMARKERS INC.: RECENT DEVELOPMENTS
PERKIN ELMER INC.
TABLE 91 PERKIN ELMER INC.: KEY PRODUCTS
QIAGEN NV
TABLE 92 QIAGEN NV: KEY PRODUCTS
TABLE 93 QIAGEN NV: RECENT DEVELOPMENTS
RADIOMETER MEDICAL
TABLE 94 RADIOMETER MEDICAL: KEY PRODUCTS
TABLE 95 RADIOMETER MEDICAL: RECENT DEVELOPMENTS
RANDOX LABORATORIES LTD.
TABLE 96 RANDOX LABORATORIES LTD.: KEY PRODUCTS
TABLE 97 RANDOX LABORATORIES LTD.: RECENT DEVELOPMENTS
RESPONSE BIOMEDICAL CORP.
TABLE 98 RESPONSE BIOMEDICAL CORP.: KEY PRODUCTS
TABLE 99 RESPONSE BIOMEDICAL CORP.: RECENT DEVELOPMENTS
ROCHE HOLDING AG
TABLE 100 ROCHE HOLDING AG: KEY PRODUCTS
TABLE 101 ROCHE HOLDING AG: RECENT DEVELOPMENTS
SIGNOSIS INC.
TABLE 102 SIGNOSIS INC.: KEY PRODUCTS
SIEMENS HEALTHCARE DIAGNOSTICS
TABLE 103 SIEMENS HEALTHCARE DIAGNOSTICS: KEY PRODUCTS
TABLE 104 SIEMENS HEALTHCARE DIAGNOSTICS: RECENT DEVELOPMENTS
SINGULEX, INC.
TABLE 105 SINGULEX, INC.: KEY PRODUCTS
TABLE 106 SINGULEX, INC.: RECENT DEVELOPMENTS
THERMO FISHER SCIENTIFIC INC.
TABLE 107 THERMO FISHER SCIENTIFIC INC: KEY PRODUCTS
TABLE 108 THERMO FISHER SCIENTIFIC INC: RECENT DEVELOPMENTS
WUXI APPTEC
TABLE 109 WUXI APPTEC’S SERVICES
TABLE 110 WUXI APPTEC: RECENT DEVELOPMENTS
POTENTIAL ENTRANTS
EVOTEC
JOHNSON & JOHNSON
MERCK AND CO. INC.
QUINTILES
CHAPTER 9 APPENDIX
TABLE 111 LIST OF PATENTS, 2006-2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report